Recent advances in the phencyclidine model of schizophrenia
1991; American Psychiatric Association; Volume: 148; Issue: 10 Linguagem: Inglês
10.1176/ajp.148.10.1301
ISSN1535-7228
AutoresDaniel C. Javitt, Stephen R. Zukin,
Tópico(s)Receptor Mechanisms and Signaling
ResumoBack to table of contents Previous article Next article No AccessRecent advances in the phencyclidine model of schizophreniaPublished Online:1 Apr 2006https://doi.org/10.1176/ajp.148.10.1301AboutSectionsView articleAbstractPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View articleAbstractOBJECTIVE: Phencyclidine (PCP, "angel dust") induces a psychotomimetic state that closely resembles schizophrenia. As opposed to amphetamine- induced psychosis, PCP-induced psychosis incorporates both positive (e.g., hallucinations, paranoia) and negative (e.g., emotional withdrawal, motor retardation) schizophrenic symptoms. PCP-induced psychosis also uniquely incorporates the formal thought disorder and neuropsychological deficits associated with schizophrenia. The purpose of the present paper is to review recent advances in the study of the molecular mechanisms of PCP action and to describe their implications for the understanding of schizophrenic pathophysiology. METHOD: Twenty- five papers were identified that described the clinical dose and serum and CSF levels at which PCP induces its psychotomimetic effects. The dose range of PCP-induced effects were compared to the dose range at which PCP interacts with specific molecular targets and affects neurotransmission. RESULTS: It was found that PCP-induced psychotomimetic effects are associated with submicromolar serum concentrations of PCP. At these concentrations PCP interacts selectively with a specific binding site (PCP receptor) that is associated with the N-methyl-D-aspartate (NMDA)-type excitatory amino acid receptor. Occupation of its receptor by PCP induces noncompetitive inhibition of NMDA receptor-mediated neurotransmission. Other NMDA antagonists such as the dissociative anesthetic ketamine induce PCP- like neurobehavioral effects in proportion to their potency in binding to the PCP receptor and inducing NMDA receptor inhibition. CONCLUSIONS: These findings suggest that endogenous dysfunction of NMDA receptor- mediated neurotransmission might contribute to the pathogenesis of schizophrenia. The relative implications of the PCP and amphetamine models of schizophrenia are discussed in relationship to the diagnosis and etiology of schizophrenia. Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited ByThe neurobiology of schizophreniaThe effect of lansoprazole on MK-801-induced schizophrenia-like behaviors in miceProgress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 120Biological hypotheses, risk factors, and biomarkers of schizophreniaProgress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 120Targeting NMDA receptors in neuropsychiatric disorders by drug screening on human neurons derived from pluripotent stem cells9 June 2022 | Translational Psychiatry, Vol. 12, No. 1Polymorphism of rs12294045 in EAAT2 gene is potentially associated with schizophrenia in Chinese Han population8 March 2022 | BMC Psychiatry, Vol. 22, No. 1Deficiency of kynurenine 3-monooxygenase exacerbates impairment of prepulse inhibition induced by phencyclidineBiochemical and Biophysical Research Communications, Vol. 629Impact of Gestational Haloperidol Exposure on miR-137-3p and Nr3c1 mRNA Expression in Hippocampus of Offspring Mice21 July 2022 | International Journal of Neuropsychopharmacology, Vol. 25, No. 10Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation24 October 2022 | Molecular Psychiatry, Vol. 133NMDA Receptor C-Terminal Domain Signalling in Development, Maturity, and Disease27 September 2022 | International Journal of Molecular Sciences, Vol. 23, No. 19An Update of Ketamine Illicit Use14 September 2022Pathway-specific contribution of parvalbumin interneuron NMDARs to synaptic currents and thalamocortical feedforward inhibition8 September 2022 | Molecular Psychiatry, Vol. 24Emerging evidence for astrocyte dysfunction in schizophrenia30 May 2022 | Glia, Vol. 70, No. 9Astrocyte Activation, but not Microglia, Is Associated with the Experimental Mouse Model of Schizophrenia Induced by Chronic Ketamine8 July 2022 | Journal of Molecular Neuroscience, Vol. 72, No. 9Pharmacokinetics and Safety of Sodium Benzoate, a d-Amino Acid Oxidase (DAAO) Inhibitor, in Healthy Subjects: A Phase I, Open-Label StudyClinical Therapeutics, Vol. 162Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanismEuropean Neuropsychopharmacology, Vol. 62Important Drug-Drug Interactions for the Addiction PsychiatristPsychiatric Clinics of North America, Vol. 45, No. 3mGlu1-mediated restoration of prefrontal cortex inhibitory signaling reverses social and cognitive deficits in an NMDA hypofunction model in mice28 May 2022 | Neuropsychopharmacology, Vol. 47, No. 10Reduced d-serine levels drive enhanced non-ionotropic NMDA receptor signaling and destabilization of dendritic spines in a mouse model for studying schizophreniaNeurobiology of Disease, Vol. 170GluN3A excitatory glycine receptors control adult cortical and amygdalar circuitsNeuron, Vol. 110, No. 15New drug targets in psychiatry: Neurobiological considerations in the genomics eraNeuroscience & Biobehavioral Reviews, Vol. 139Impact of clozapine on the expression of miR-675-3p in plasma exosomes derived from patients with schizophrenia29 July 2022 | The World Journal of Biological Psychiatry, Vol. 45The genetic architecture of schizophrenia: review of large-scale genetic studies12 July 2022 | Journal of Human Genetics, Vol. 388Medial Septum Modulates Consciousness and Psychosis-Related Behaviors Through Hippocampal Gamma Activity7 July 2022 | Frontiers in Neural Circuits, Vol. 16Probing the molecular and cellular pathological mechanisms of schizophrenia using human induced pluripotent stem cell modelsSchizophrenia Research, Vol. 48Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease16 June 2022 | Pharmacological Reviews, Vol. 74, No. 3Effect of dopamine receptor-related compounds on naïve common marmosets for auditory steady-state responseJournal of Neurophysiology, Vol. 128, No. 1Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics29 June 2022 | Biomolecules, Vol. 12, No. 7Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia10 June 2022 | Molecular Psychiatry, Vol. 31Repeated intermittent administration of (R)-ketamine during juvenile and adolescent stages prevents schizophrenia-relevant phenotypes in adult offspring after maternal immune activation: a role of TrkB signaling3 January 2022 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 272, No. 4Ion flux-independent NMDA receptor signalingNeuropharmacology, Vol. 210Differential expression of miR-148b, miR-129-2 and miR-296 in animal models of schizophrenia-Relevance to NMDA receptor hypofunctionNeuropharmacology, Vol. 210Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia14 April 2022 | Molecular Psychiatry, Vol. 27, No. 5Structural and Functional Deviations of the Hippocampus in Schizophrenia and Schizophrenia Animal Models13 May 2022 | International Journal of Molecular Sciences, Vol. 23, No. 10Ketamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic?27 April 2022 | Molecular Psychiatry, Vol. 6Schizophrenia Genomics: Convergence on Synaptic Development, Adult Synaptic Plasticity, or Both?Biological Psychiatry, Vol. 91, No. 8The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to diseaseSchizophrenia Research, Vol. 242Edward F. Domino, Ph.D. (1924–2021)1 February 2022 | Neuropsychopharmacology, Vol. 47, No. 5Behavioural and molecular characterisation of the Dlg2 haploinsufficiency rat model of genetic risk for psychiatric disorder25 January 2022 | Genes, Brain and Behavior, Vol. 21, No. 4Discovery of Subtype Selective Agonists of the Group II Metabotropic Glutamate Receptors11 March 2022MK212, a 5-hydroxytryptamine 2C receptor agonist, reverses prepulse inhibition deficits in the medial prefrontal cortex and ventral hippocampusProgress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 113Glutamate NMDA Receptor Antagonists with Relevance to Schizophrenia: A Review of Zebrafish Behavioral StudiesCurrent Neuropharmacology, Vol. 20, No. 3Present and future antipsychotic drugs: A systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational perspectivePharmacological Research, Vol. 176Autoimmune PsychosisUlotaront: A TAAR1 Agonist for the Treatment of Schizophrenia6 December 2021 | ACS Medicinal Chemistry Letters, Vol. 13, No. 1Cognitive [Computational] Neuroscience Test Reliability and Clinical Applications for Serious Mental Illness (CNTRaCS) Consortium: Progress and Future Directions30 September 2022Glutamate, Glutamatergic Drugs and Schizophrenia11 April 2022CNS Glutamate in Impulsive Aggression11 April 2022ArylcyclohexaminesSchizophreniaThe Lancet, Vol. 399, No. 10323Phencyclidine (PCP)-induced neurotoxicity and behavioral deficitsTarget selection for deep brain stimulation in treatment resistant schizophreniaProgress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 112Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor7 May 2021 | Molecular Psychiatry, Vol. 27, No. 1Relationship Between Replay-Associated Ripples and Hippocampal N -Methyl-D-Aspartate Receptors: Preliminary Evidence From a PET-MEG Study in Schizophrenia7 July 2022 | Schizophrenia Bulletin Open, Vol. 3, No. 1Pharmacologically induced N‐methyl‐D‐aspartate receptor hypofunction impairs goal‐directed food seeking in rats20 September 2021 | Neuropsychopharmacology Reports, Vol. 41, No. 4Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes10 March 2021 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 271, No. 8Global Scientific Outputs of Schizophrenia Publications From 1975 to 2020: a Bibliometric Analysis3 August 2021 | Psychiatric Quarterly, Vol. 92, No. 4The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study17 July 2021 | Translational Psychiatry, Vol. 11, No. 1N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study12 August 2021 | Translational Psychiatry, Vol. 11, No. 1The beta component of gamma-band auditory steady-state responses in patients with schizophrenia14 October 2021 | Scientific Reports, Vol. 11, No. 1Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies7 December 2021 | International Journal of Molecular Sciences, Vol. 22, No. 24mGlu1 potentiation enhances prelimbic somatostatin interneuron activity to rescue schizophrenia-like physiological and cognitive deficitsCell Reports, Vol. 37, No. 5Calcium channels and iron metabolism: A redox catastrophe in Parkinson's disease and an innovative path to novel therapies?Redox Biology, Vol. 47Evidence for Reduced Long-Term Potentiation-Like Visual Cortical Plasticity in Schizophrenia and Bipolar Disorder8 May 2021 | Schizophrenia Bulletin, Vol. 47, No. 6Evaluation of acute and chronic nociception in subchronically administered MK-801-induced rat model of schizophreniaBehavioural Pharmacology, Vol. 32, No. 7Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels21 January 2022 | Pharmacological Reviews, Vol. 73, No. 4Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia1 October 2021 | Frontiers in Psychiatry, Vol. 12Brain Versus Blood: A Systematic Review on the Concordance Between Peripheral and Central Kynurenine Pathway Measures in Psychiatric Disorders23 September 2021 | Frontiers in Immunology, Vol. 12Circuits and Synapses: Hypothesis, Observation, Controversy and Serendipity – An Opinion Piece16 September 2021 | Frontiers in Neural Circuits, Vol. 15[ 18 F]ALX5406: A Brain-Penetrating Prodrug for GlyT1-Specific PET Imaging27 August 2021 | ACS Chemical Neuroscience, Vol. 12, No. 18Chronic presence of blood circulating anti-NMDAR1 autoantibodies impairs cognitive function in mice2 September 2021 | PLOS ONE, Vol. 16, No. 9Impaired discrimination of a subanesthetic dose of ketamine in a maternal immune activation model of schizophrenia risk6 July 2021 | Journal of Psychopharmacology, Vol. 35, No. 9Detection of Morphological Abnormalities in Schizophrenia: An Important Step to Identify Associated Genetic Disorders or Etiologic Subtypes31 August 2021 | International Journal of Molecular Sciences, Vol. 22, No. 17Src and Fyn regulation of NMDA receptors in health and diseaseNeuropharmacology, Vol. 193Serotonergic–Muscarinic Interaction within the Prefrontal Cortex as a Novel Target to Reverse Schizophrenia-Related Cognitive Symptoms10 August 2021 | International Journal of Molecular Sciences, Vol. 22, No. 16Involvement of Kynurenine Metabolism in Bipolar Disorder: An Updated Review26 July 2021 | Frontiers in Psychiatry, Vol. 12Interneuron Heterotopia in the Lis1 Mutant Mouse Cortex Underlies a Structural and Functional Schizophrenia-Like Phenotype13 July 2021 | Frontiers in Cell and Developmental Biology, Vol. 9White Matter Neurometabolic Signatures Support the Deficit and Nondeficit Distinction in Antipsychotic-Naïve First-Episode Psychosis Patients8 March 2021 | Schizophrenia Bulletin, Vol. 47, No. 4Perturbations in the catecholamine metabolism and protective effect of “3-(3, 4-dimethoxy phenyl)-1-4(methoxy phenyl) prop-2-en-1-one” during ketamine-induced schizophrenia: an in vivo and in silico studies18 May 2020 | Journal of Biomolecular Structure and Dynamics, Vol. 39, No. 10Experimental Models of Cognitive Impairments in Schizophrenia9 September 2021 | Neuroscience and Behavioral Physiology, Vol. 51, No. 6New insights on nitric oxide: Focus on animal models of schizophreniaBehavioural Brain Research, Vol. 409NMDARs in prefrontal cortex – Regulation of synaptic transmission and plasticityNeuropharmacology, Vol. 192Increased excitation-inhibition balance and loss of GABAergic synapses in the serine racemase knockout model of NMDA receptor hypofunctionJournal of Neurophysiology, Vol. 126, No. 1Ketamine Alters Functional Gamma and Theta Resting-State Connectivity in Healthy Humans: Implications for Schizophrenia Treatment Targeting the Glutamate System10 June 2021 | Frontiers in Psychiatry, Vol. 12Physiology and Therapeutic Potential of SK, H, and M Medium AfterHyperPolarization Ion Channels3 June 2021 | Frontiers in Molecular Neuroscience, Vol. 14Neuroimaging Biomarkers in SchizophreniaNina V. Kraguljac, M.D., William M. McDonald, M.D., Alik S. Widge, M.D., Ph.D., Carolyn I. Rodriguez, M.D., Ph.D., Mauricio Tohen, M.D., Dr.P.H., Charles B. Nemeroff, M.D., Ph.D.5 January 2021 | American Journal of Psychiatry, Vol. 178, No. 6Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study28 September 2020 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 271, No. 4Stem cell-based models and therapies: a key approach into schizophrenia treatment2 January 2021 | Cell and Tissue Banking, Vol. 22, No. 2Multiple nicotinic acetylcholine receptor subtypes regulate social or cognitive behaviors in mice repeatedly administered phencyclidineBehavioural Brain Research, Vol. 408Therapeutic potentiality of a new flavonoid against ketamine induced glutamatergic dysregulation in schizophrenia: In vivo and in silico approachBiomedicine & Pharmacotherapy, Vol. 138Resting-state dopaminergic cell firing in the ventral tegmental area negatively regulates affiliative social interactions in a developmental animal model of schizophrenia22 April 2021 | Translational Psychiatry, Vol. 11, No. 1Antipsychotic Agents26 April 2021Neural rhythm in the retrosplenial cortex during ketamine-induced dissociation12 January 2021 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 271, No. 3Use and abuse of dissociative and psychedelic drugs in adolescencePharmacology Biochemistry and Behavior, Vol. 203Visual cortical plasticity and the risk for psychosis: An interim analysis of the North American Prodrome Longitudinal StudySchizophrenia Research, Vol. 230Impairment of Executive Functions Associated With Lower D-Serine Serum Levels in Patients With Schizophrenia29 March 2021 | Frontiers in Psychiatry, Vol. 12Neuroimaging as a Window Into the Pathophysiological Mechanisms of Schizophrenia11 March 2021 | Frontiers in Psychiatry, Vol. 12P.302 N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging studyEuropean Neuropsychopharmacology, Vol. 44Efficacy of N -methyl- D -aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials6 January 2021 | Journal of Psychopharmacology, Vol. 35, No. 3Modulation of NMDA Receptors by G-protein-coupled receptors: Role in Synaptic Transmission, Plasticity and BeyondNeuroscience, Vol. 456Using iPSC Models to Understand the Role of Estrogen in Neuron–Glia Interactions in Schizophrenia and Bipolar Disorder21 January 2021 | Cells, Vol. 10, No. 2Crocins, the Bioactive Components of Crocus sativus L., Counteract the Disrupting Effects of Anesthetic Ketamine on Memory in Rats20 January 2021 | Molecules, Vol. 26, No. 3Animal Models for Brain Research30 September 2020Molecular Imaging in Schizophrenia Spectrum Disorders15 December 2020Substance Use PsychosisMismatch-negativity (MMN) in animal models: Homology of human MMN?Hearing Research, Vol. 399Progressive Changes in Glutamate Concentration in Early Stages of Schizophrenia: A Longitudinal 7-Tesla MRS Study2 February 2021 | Schizophrenia Bulletin Open, Vol. 2, No. 1International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function22 December 2020 | Pharmacological Reviews, Vol. 73, No. 1Dissociating the effects of distraction and proactive interference on object memory through tests of novelty preference27 April 2021 | Brain and Neuroscience Advances, Vol. 5Astrocytes in schizophrenia27 April 2021 | Brain and Neuroscience Advances, Vol. 5Cognitive Impact by Blood Circulating Anti-NMDAR1 Autoantibodies1 January 2021 | Journal of Psychiatry and Brain Science, Vol. 148Involvement of nicotinic acetylcholine receptors in behavioral abnormalities and psychological dependence in schizophrenia-like model miceEuropean Neuropsychopharmacology, Vol. 41In silico hippocampal modeling for multi-target pharmacotherapy in schizophrenia21 September 2020 | npj Schizophrenia, Vol. 6, No. 1P2X7 Receptor-Dependent Layer-Specific Changes in Neuron-Microglia Reactivity in the Prefrontal Cortex of a Phencyclidine Induced Mouse Model of Schizophrenia11 November 2020 | Frontiers in Molecular Neuroscience, Vol. 13Structural features of the glutamate-binding protein from Corynebacterium glutamicumInternational Journal of Biological Macromolecules, Vol. 162Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects10 June 2020 | British Journal of Clinical Pharmacology, Vol. 86, No. 11Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions26 October 2020 | International Journal of Molecular Sciences, Vol. 21, No. 21Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery20 November 2020 | International Journal of Molecular Sciences, Vol. 21, No. 22Automated design and optimization of multitarget schizophrenia drug candidates by deep learningEuropean Journal of Medicinal Chemistry, Vol. 204The integrated model of glutamate and dopamine hypothesis for schizophrenia: Prediction and personalized medicine for prevent potential treatment-resistant patientsMedical Hypotheses, Vol. 143Ketamine disrupted storage but not retrieval of information in male rats and apomorphine counteracted its impairing effectNeuroscience Letters, Vol. 737Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers13 May 2020 | Neuropsychopharmacology, Vol. 45, No. 11Do damaging variants of SLC6A9, the gene for the glycine transporter 1 (GlyT-1), protect against schizophrenia?10 August 2020 | Psychiatric Genetics, Vol. 30, No. 5Magnetic Resonance Spectroscopy (MRS) in Psychiatric Diseases12 November 2020Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches11 August 2020 | CNS Drugs, Vol. 34, No. 9The nicotinic α7 receptor agonist GTS-21 but not the nicotinic α4β2 receptor agonist ABT-418 attenuate the disrupting effects of anesthetic ketamine on recognition memory in ratsBehavioural Brain Research, Vol. 393Latent inhibition and its potential as a biomarker for schizophreniaBiomarkers in NeuropsychiatryAdolescent cannabinoid exposure interacts with other risk factors in schizophrenia: A review of the evidence from animal modelsNeuroscience & Biobehavioral Reviews, Vol. 116Glutamate in schizophrenia: Neurodevelopmental perspectives and drug developmentSchizophrenia Research, Vol. 223Antipsychotic-like profile of CIQ isomers in animal models of schizophrenia18 December 2019 | Behavioural Pharmacology, Vol. 31, No. 6The Gut Microbiome in Psychosis From Mice to Men: A Systematic Review of Preclinical and Clinical Studies11 August 2020 | Frontiers in Psychiatry, Vol. 11The NIMH ‘Fast-Fail Trials’ (FAST) Initiative: Rationale, Promise, and Progress23 July 2020 | Pharmaceutical Medicine, Vol. 34, No. 4Schizophrenia: A HomecomingBiological Psychiatry, Vol. 88, No. 4Pharmacodynamic elucidation of glutamate & dopamine in ketamine-induced anaesthesiaChemico-Biological Interactions, Vol. 327Treatment effects on neurometabolite levels in schizophrenia: A systematic review and meta-analysis of proton magnetic resonance spectroscopy studiesSchizophrenia Research, Vol. 222Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study21 May 2020 | Journal of Psychopharmacology, Vol. 34, No. 8Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?31 July 2020 | Biomolecules, Vol. 10, No. 8Multi-Scale Understanding of NMDA Receptor Function in Schizophrenia11 August 2020 | Biomolecules, Vol. 10, No. 8Effects of (+)-bicuculline, a GABAa receptor antagonist, on auditory steady state response in free-moving rats24 July 2020 | PLOS ONE, Vol. 15, No. 7MK-801 impairs working memory on the Trial-Unique Nonmatch-to-Location test in mice, but this is not exclusively mediated by NMDA receptors on PV+ interneurons or forebrain pyramidal cellsNeuropharmacology, Vol. 171The polygenic architecture of schizophrenia — rethinking pathogenesis and nosology11 June 2020 | Nature Reviews Neurology, Vol. 16, No. 7Hispidulin attenuates the social withdrawal in isolated disrupted‐in‐schizophrenia‐1 mutant and chronic phencyclidine‐treated mice3 April 2020 | British Journal of Pharmacology, Vol. 177, No. 14Interaction between Mesocortical and Mesothalamic Catecholaminergic Transmissions Associated with NMDA Receptor in the Locus Coeruleus1 July 2020 | Biomolecules, Vol. 10, No. 7Translational neurophysiological biomarkers of N-methyl-d-aspartate receptor dysfunction in serine racemase knockout miceBiomarkers in Neuropsychiatry, Vol. 2Digital autoradiography for efficient functional imaging without anesthesia in experimental animals: Reversing phencyclidine-induced functional alterations using clozapineProgress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 100Glutamate metabolites in treatment resistant schizophrenia: A meta-analysis and systematic review of 1H-MRS studiesPsychiatry Research: Neuroimaging, Vol. 300White matter alterations and the conversion to psychosis: A combined diffusion tensor imaging and glutamate 1H MRS studySchizophrenia ResearchDrugs of Abuse and the Nervous SystemCONTINUUM: Lifelong Learning in Neurology, Vol. 26, No. 3Brain NMDA Receptors in Schizophrenia and Depression23 June 2020 | Biomolecules, Vol. 10, No. 6Electoretinographic evidence of retinal ganglion cell-dependent function in schizophreniaSchizophrenia Research, Vol. 219Circuits and functions of the lateral habenula in health and in disease8 April 2020 | Nature Reviews Neuroscience, Vol. 21, No. 5Plasma levels of dopamine metabolite correlate with mismatch negativity in patients with schizophrenia15 February 2020 | Psychiatry and Clinical Neurosciences, Vol. 74, No. 5Computational modeling of excitatory/inhibitory balance impairments in schizophreniaSchizophrenia ResearchPsychosis in Parkinson’s disease and parkinsonism in antipsychotic-naive schizophrenia spectrum psychosis: clinical, nosological and pathobiological challenges5 March 2020 | Acta Pharmacologica Sinica, Vol. 41, No. 4Evidence that alpha blocking is due to increases in system-level oscillatory damping not neuronal population desynchronisationNeuroImage, Vol. 208Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study16 December 2019 | Neuropsychopharmacology, Vol. 45, No. 4Electroretinographic Abnormalities and Sex Differences Detected with Mesopic Adaptation in a Mouse Model of Schizophrenia: A and B Wave AnalysisInvestigative Opthalmology & Visual Science, Vol. 61, No. 2Neuroprotection in glaucoma‑electrophysiology (Review)10 February 2020 | Experimental and Therapeutic MedicineDopamine and glutamate in schizophrenia: biology, symptoms and treatment10 January 2020 | World Psychiatry, Vol. 19, No. 1Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathwaysBehavioural Brain Research, Vol. 380The D2-family receptor agonist bromocriptine but, not nicotine, reverses NMDA receptor antagonist-induced working memory deficits in the radial arm maze in miceNeurobiology of Learning and Memory, Vol. 168Immune and Neuroendocrine Trait and State Markers in Psychotic Illness: Decreased Kynurenines Marking Psychotic Exacerbations17 January 2020 | Frontiers in Immunology, Vol. 10Adverse pharmacokinetic interactions between illicit substances and clinical drugs11 December 2019 | Drug Metabolism Reviews, Vol. 52, No. 1Attenuated Psychosis Syndrome6 February 2020SchizophreniaSerotonin and schizophreniaASP2905, a specific inhibitor of the potassium channel Kv12.2 encoded by the Kcnh3 gene, is psychoactive in miceBehavioural Brain Research, Vol. 378GluN2A NMDA Receptor Enhancement Improves Brain Oscillations, Synchrony, and Cognitive Functions in Dravet Syndrome and Alzheimer’s Disease ModelsCell Reports, Vol. 30, No. 2Virtual screening-driven discovery of dual 5-HT6/5-HT2A re
Referência(s)